References
- Coco-Martin RM, Sanchez-Tocino HT, Desco C, Usategui-Martín R, Tellería JJ. PRPH2-related retinal diseases: broadening the clinical spectrum and describing a new mutation. Genes. 2020;11(7):773. doi:https://doi.org/10.3390/genes11070773.
- Duncan JL, Talcott KE, Ratnam K, Sundquist SM, Lucero AS, Day S, Zhang Y, Roorda A. Cone structure in retinal degeneration associated with mutations in the peripherin/RDS gene. Invest Ophthalmol Vis Sci. 2011;52(3):1557–66. doi:https://doi.org/10.1167/iovs.10-6549.
- Chakraborty D, Strayve DG, Makia MS, Conley SM, Kakahel M, Al-Ubaidi MR, Naash MI. Novel molecular mechanisms for Prph2-associated pattern dystrophy. FASEB J. 2020;34(1):1211–30. doi:https://doi.org/10.1096/fj.201901888R.
- Zulliger R, Conley SM, Mwoyosvi ML, Al-Ubaidi MR, Naash MI. Oligomerization of Prph2 and Rom1 is essential for photoreceptor outer segment formation. Hum Mol Genet. 2018;27(20):3507–18. doi:https://doi.org/10.1093/hmg/ddy240.
- Boon CJ, van Schooneveld MJ, Den Hollander AI, van Lith-Verhoeven JJ, Zonneveld-Vrieling MN, Theelen T, Cremers FP, Hoyng CB, Klevering BJ. Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. Br J Ophthalmol. 2007;91(11):1504–11. doi:https://doi.org/10.1136/bjo.2007.115659.
- Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina (Philadelphia, Pa). 2003;23(2):171–76. doi:https://doi.org/10.1097/00006982-200304000-00006.
- Nangia P, Shah D, Saurabh K, Roy R. Efficacy of anti-VEGF in the treatment of choroidal neovascular membrane secondary to pattern dystrophy simulating fundus flavimaculatus. GMS Ophthalmol Cases. 2019;9:Doc21. doi:https://doi.org/10.3205/oc000110.
- Lee CS, Leys M, Family A. Affected by novel C213W mutation in PRPH2: long-term follow-up of CNV secondary to pattern dystrophy. Ophthalmic Surg Lasers Imaging Retina. 2020;51(6):354–62. doi:https://doi.org/10.3928/23258160-20200603-06.